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We have read with great interest the article in press of
Aurilio et al., A meta-analysis of oestrogen receptor, pro-
gesterone receptor and human epidermal growth factor
receptor 2 discordance between primary breast cancer
and metastases (http://dx.doi.org/10.1016/j.ejca.2003.
10.004), which will appear in Eur J Cancer. In the paper,
the Authors have performed a meta-analysis of the stud-
ies published in the literature concerning the discor-
dance rate in oestrogen receptor (ER), progesterone
receptor (PgR) and HER2 status between primary
tumour and corresponding relapse. It is well known that
a considerable controversy concerns the issue of hor-
mone receptors (HRs) expression as well as HER2 sta-
tus between primary breast carcinomas (BC) and
metastatic sites from the same patient, as elsewherereported in literature [1–5]. In particular, the discor-
dance between primary BC and metastases from nega-
tive to positive and vice versa potentially aﬀects the
treatment regimen [5]; therefore, it has been suggested
that neoplastic tissue of metastatic lesions should be sys-
tematically re-biopsied to optimally re-assess HR as well
as HER2 [1,2,4–8].
In their meta-analysis, focusing on HER2 status,
Aurilio et al. documented that the pooled discordance
proportion with respect to the primary breast tumour
was 10% for distant metastases and 6% for loco-regional
relapses. Moreover, a diﬀerent pooled discordant pro-
portion was found on the basis of the diﬀerent utilised
technique, since it was 10% in studies using immunohis-
tochemistry (IHC) and ﬂuorescence in situ hybridisation
(FISH), but 5% in studies using IHC only; therefore,
they conclude the observed discrepancy was not merely
due to technicality. Nevertheless, whether these changes
in HER2 status may be attributed to laboratory repro-
ducibility in techniques or to other pre-analytical fac-d human
2 A. Ieni et al. / European Journal of Cancer xxx (2014) xxx–xxxtors, such as not standardised inadequate ﬁxation or,
otherwise, to biological modiﬁcations and heterogeneity
in tumours, still remains to be clariﬁed. On the other
hand, the hypothesis that variation in HER2 status
may reﬂect clonal genome evolution has been stressed
[7]; consequently, tumour heterogeneity may be attribut-
able to tumour biological trend leading to clonal selec-
tion with the development of new clones, previously
undetectable within the primary breast cancer. In any
case, the signiﬁcant discordance between HER2 status
in the comparison of primary and recurrent/metastatic
breast carcinomas may inﬂuence the correct treatment,
determining an inappropriate use of targeted therapies
[8–11].
In this intriguing ﬁeld of breast pathology, we have
started a retrospective multi-institution analysis to
assess the discordance rate of HER2 status, not only
in recurrent or distant metastatic breast lesions, but also
taking into consideration the comparison between pri-
mary breast tumours and corresponding synchronous
nodal metastases. For this purpose, 148 patients (mean
age 59.27 years; range 33–96) not subjected to chemo-
therapy, were collected and retrospectively analysed
from ﬁve italian anatomo-pathological units. Data
concerning histotype, grading, hormone receptors
expression, growth fraction (Ki67 LI) and HER2 status
were largely available. Additionally, 14 metachronousTable 1
Histopathological features and HER2 status changes in primary invasive d
Parameters Concordance T/N
All cases (+/+)
HER2 status 141 52
pT 96 42
T1 37 (94.9%) 15
T2 40 (95.2%) 18
T3 10 (90.9%) 5
T4 9 (100%) 4
pN 97 42
N1 38 (92.7%) 17
N2 39 (92.9%) 15
N3 20 (95.2%) 10
Grade 110 44
G1 4 (100%) 0
G2 48 (94.1%) 14
G3 58 (93.5%) 30
Oestrogen receptor (ER) status 111 44
ER + 80 (93.0%) 22
ER  31 (96.9%) 22
Partial response (PR) status 110 44
PR + 73 (92.4%) 17
PR  37 (97.4%) 27
Ki67 111 44
KI 67 614% 35 (97.2%) 7
KI 67 >14% 76 (93.8%) 37
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Patient personal details were non-identiﬁable and all
patients had provided written consent to their medical
information being used for research purposes, according
with the Helsinki declaration.
For each case, 4 lm-thick sections from formalin-ﬁxed
paraﬃn-embedded tissue blocks were set for immunohis-
tochemistry. In particular, the IHC analysis for HER2 sta-
tus was done by automated workstation (DAKO
Autostainer Link48) according to manufacturer’s prod-
ucts and DAKO HercepTeste kit; in each pathological
unit, HER2 positivity was deﬁned as 3+, when strong
membranous staining in at least 30% cells was noted.FISH
analysis was performed usingHER2FISHPharmDxe kit
(Dako, Glostrup, Denmark) if previous IHC showed 2+
immunostaining (weak or moderate complete membra-
nous staining of 10–30% of tumours cells); gene ampliﬁca-
tion was recorded when HER2 to CEP17 signal ratio was
P2.0. All immunostained slides were reassessed by two
observers (A.I. andG.T.), blinded of previous paired data,
and the results were scored in a random order. The inter-
observer kappa (j) index in HER2 status determination
was of 0.78, representing a substantial agreement; when
an inter-observer disagreement emerged, cases were jointly
discussed until an agreement was reached. The
Chi-square test was utilised to compare HER2 status with
other biological parameters.uctal carcinomas and corresponding metastatic lymph nodes analysed.
Discordance T/N
(/) All cases (+/) (/+)
89 7 4 3
54 7 4 3
22 2 (5.1%) 1 1
22 3 (7.0%) 2 1
5 2 (16.7%) 1 1
5 0 0 0
55 7 4 3
21 3 (7.3%) 1 2
24 3 (7.1%) 2 1
10 1 (4.8%) 1 0
66 7 4 3
4 0 0 0
34 3 (5.9%) 2 1
28 4 (6.5%) 2 2
67 7 4 3
58 6 (7.0%) 3 3
9 1 (3.1%) 1 0
66 7 4 3
56 6 (7.6%) 3 3
10 1 (2.6%) 1 0
67 6 4 2
28 1 (2.8%) 0 1
39 5 (6.2%) 4 1
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Table 1. The whole concordance rate for HER2 was
95.2%; in detail, 89 cases were concordantly HER2 neg-
ative either in primary breast carcinoma or in node
metastases, while 52 cases were HER2 positive in both
samples. Changes in HER2 status between primary
invasive ductal carcinomas and corresponding meta-
static lymph nodes were found with a pooled discordant
rate of 4.8%. The discordance involved seven cases:
three of which, primarily negative, became positive
(2.1%) while, by contrast, the original immunopositivity
for HER2 disappeared in four cases (2.7%). Moreover, a
discordance rate was also appreciable in the compara-
tive analysis between primary carcinomas and metach-
ronous recurrences; in particular, 1/14 cases (7.14%)
revealed a 3+ immunoreactivity in secondary relapsed
skin lesion, while the primary breast lesion was initially
scored 0.
No relationships emerged between HER2 status and
hormone receptors, growth fraction and other clinico-
pathological ﬁndings (pT, pN, grade).
In conclusion, discordance in HER2 expression
between primary and lymph node breast cancer seems
to be ascertained by our multiple-institution analysis.
The appearance of changes in HER2 status during the
natural history of breast cancer may inﬂuence the clini-
cal decision of oncologists; in fact, while the shift from
positive to negative suggests to maintain the Trast-
uzumab as treatment choice, by contrast the opposite
shift from negative to positive should be evaluated by
a simultaneous HER2 determination in both primary
and lymph node breast cancer lesions, inﬂuencing thus
the targeted therapeutic protocol.
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